Project Name：Dasatinib 

Registration Classification：3+6

Indications：This product is suitable for diseases including imatinib mesylate , including resistant or intolerant chronic myeloid leukemia (CML) all stage of disease ( chronic phase , accelerated phase , lymphocytes and myeloid blast crisis stage period ) . Philadelphia can be used in addition to the conventional therapy resistant or intolerant chromosome positive acute lymphoblastic leukemia (Ph + CML All), adult patients only.

Original Research Company：Bristol-Myers Squibb Pharma EEIG. 

Progress ：Pharmaceutical Research in progress